| Name | Title | Contact Details |
|---|
Unlocking the health benefits of cannabinoids. Learn More Unlocking the health benefits on cannabinoidsLearn more We are a team of medical experts. Meet our team https://sanitygroup.com/wp-content/uploads/2020/11/SP_Homepage_Video_Compressed_BW.mp4 Med...
06795 Pfizer Inc. is an American multinational pharmaceutical corporation headquartered in New York City.
We are a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire`s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.